《股市简讯》中国复宏汉霖一度涨4.7%，肺癌联合疗法临床试验获批

路透中文

03/17

《股市简讯》中国<a href="https://laohu8.com/S/02696">复宏汉霖</a>一度涨4.7%，肺癌联合疗法临床试验获批

* 中国复星医药2196.HK600196.SS旗下研发生物类似药的复宏汉霖2696.HK周二早盘一度升4.7%，早市收高1.7%。

* 该公司此前公告称，HLX07联合汉斯状（斯鲁利单抗注射液）和化疗治疗晚期鳞状非小细胞肺癌的临床试验申请获国家药品监督管理局批准。

* 复宏汉霖今年迄今劲涨21.1%，同期恒生指数.HSI上扬1.8%。

* 恒⽣⽣物科技指数.HSBIO早市收高2.3%。（完）

更多股市简讯请点选CN-CMN-HOT

(发稿徐凯文；审校吴云凌)

((kaiwen.xu@thomsonreuters.com))

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2620008417"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620008417\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620008417?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-03-17 12:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620008417","market":"us","top_or_hot":-1,"title":"《股市简讯》中国复宏汉霖一度涨4.7%，肺癌联合疗法临床试验获批","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>《股市简讯》中国<a href=\"https://laohu8.com/S/02696\">复宏汉霖</a>一度涨4.7%，肺癌联合疗法临床试验获批</title></head><body><p>* 中国<a href=\"https://laohu8.com/S/600196\">复星医药</a><span>2196.HK</span><span>600196.SS</span>旗下研发<a href=\"https://laohu8.com/S/000504\">生物</a>类似药的复宏汉霖<span>2696.HK</span>周二早盘一度升4.7%，早市收高1.7%。</p><p>* 该公司此前公告称，HLX07联合汉斯状（斯鲁利单抗注射液）和化疗治疗晚期鳞状非小细胞肺癌的临床试验申请获国家药品监督管理局批准。</p><p>* 复宏汉霖今年迄今劲涨21.1%，同期恒生指数<span>.HSI</span>上扬1.8%。</p><p>* 恒⽣⽣物科技指数<span>.HSBIO</span>早市收高2.3%。（完）</p><p>更多股市简讯请点选<span>CN-CMN-HOT</span></p><p> (发稿 徐凯文；审校 吴云凌)</p><p> ((kaiwen.xu@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>《股市简讯》中国复宏汉霖一度涨4.7%，肺癌联合疗法临床试验获批</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n《股市简讯》中国复宏汉霖一度涨4.7%，肺癌联合疗法临床试验获批\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2026-03-17 12:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>《股市简讯》中国<a href=\"https://laohu8.com/S/02696\">复宏汉霖</a>一度涨4.7%，肺癌联合疗法临床试验获批</title></head><body><p>* 中国<a href=\"https://laohu8.com/S/600196\">复星医药</a><span>2196.HK</span><span>600196.SS</span>旗下研发<a href=\"https://laohu8.com/S/000504\">生物</a>类似药的复宏汉霖<span>2696.HK</span>周二早盘一度升4.7%，早市收高1.7%。</p><p>* 该公司此前公告称，HLX07联合汉斯状（斯鲁利单抗注射液）和化疗治疗晚期鳞状非小细胞肺癌的临床试验申请获国家药品监督管理局批准。</p><p>* 复宏汉霖今年迄今劲涨21.1%，同期恒生指数<span>.HSI</span>上扬1.8%。</p><p>* 恒⽣⽣物科技指数<span>.HSBIO</span>早市收高2.3%。（完）</p><p>更多股市简讯请点选<span>CN-CMN-HOT</span></p><p> (发稿 徐凯文；审校 吴云凌)</p><p> ((kaiwen.xu@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000306701.USD","symbol_name":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nL4T4050CI:1","article_id":"2620008417","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620008417","pubTimestamp":1773721517,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"《股市简讯》中国复宏汉霖一度涨4.7%，肺癌联合疗法临床试验获批* 中国复星医药2196.HK600196.SS旗下研发生物类似药的复宏汉霖2696.HK周二早盘一度升4.7%，早市收高1.7%。* 该公司此前公告称，HLX07联合汉斯状（斯鲁利单抗注射液）和化疗治疗晚期鳞状非小细胞肺癌的临床试验申请获国家药品监督管理局批准。* 复宏汉霖今年迄今劲涨21.1%，同期恒生指数.HSI上扬1.8%。* 恒⽣⽣物科技指数.HSBIO早市收高2.3%。（完）更多股市简讯请点选CN-CMN-HOT (发稿 徐凯文；审校 吴云凌) ((kaiwen.xu@thomsonreuters.com))","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","02696":"复宏汉霖","BK1161":"生物科技","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC"},"translate_title":"\"Stock Market Newsletter\" China Fuhong Henlius once rose 4.7%, and the clinical trial of lung cancer combination therapy was approved","themeId":"37684715aaf54a73b9fe52ee56a263cc","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":0.9},"content_text":"《股市简讯》中国复宏汉霖一度涨4.7%，肺癌联合疗法临床试验获批* 中国复星医药2196.HK600196.SS旗下研发生物类似药的复宏汉霖2696.HK周二早盘一度升4.7%，早市收高1.7%。* 该公司此前公告称，HLX07联合汉斯状（斯鲁利单抗注射液）和化疗治疗晚期鳞状非小细胞肺癌的临床试验申请获国家药品监督管理局批准。* 复宏汉霖今年迄今劲涨21.1%，同期恒生指数.HSI上扬1.8%。* 恒⽣⽣物科技指数.HSBIO早市收高2.3%。（完）更多股市简讯请点选CN-CMN-HOT (发稿 徐凯文；审校 吴云凌) ((kaiwen.xu@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}